All Stories

J&J ties early-stage lymphoma CAR-T to 100% response rate in 10 patients

Johnson and Johnson is providing a first look at clinical data for its dual-targeting blood cancer CAR-T program.

Jun 13, 2025 - 19:00
 0
J&J ties early-stage lymphoma CAR-T to 100% response rate in 10 patients
Johnson and Johnson is providing a first look at clinical data for its dual-targeting blood cancer CAR-T program.
Read More

Tags:

Previous Article

Matière Première ouvre un flagship parisien pensé comme le reflet de son ADN

Next Article

Huntington Disease Digital Motor Score Can Enhance Progression Detection

Related Posts

Endometrial cancer data on Genmab’s Elahere rival beat forecast, fueling push into phase 3

Endometrial cancer data on Genmab’s Elahere rival beat ...

May 23, 2025  0

ASCO: AstraZeneca's oral SERD tied to 56% PFS benefit in phase 3 breast cancer trial

ASCO: AstraZeneca's oral SERD tied to 56% PFS benefit i...

Jun 2, 2025  0

ASCO’s bubble of hope: Execs focus on ‘rewriting textbooks’ in cancer care at conference

ASCO’s bubble of hope: Execs focus on ‘rewriting textbo...

Jun 2, 2025  0